A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps

Journal of Human Nutrition and Dietetics

Volumn 30, Issue 5, 2017, Pages 545-553

  Teasdale, S B ^a,b   Samaras, K ^c,d   Wade, T ^a   Jarman, R ^a   Ward, P B ^b,e  

^a SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

Author keywords

diet; mental illness; nutrition; psychosis; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

DIET; DIET THERAPY; DIETARY REFERENCE INTAKE; DIETITIAN; FOOD DRUG INTERACTION; HUMAN; LIFESTYLE; MENTAL DISEASE; OBESITY;

ANTIPSYCHOTIC AGENTS; DIET; FOOD-DRUG INTERACTIONS; HUMANS; LIFE STYLE; MENTAL DISORDERS; NUTRITIONISTS; OBESITY; RECOMMENDED DIETARY ALLOWANCES;

EID: 85017531563     PISSN: 09523871     EISSN: 1365277X     Source Type: Journal    
DOI: 10.1111/jhn.12473     Document Type: Review

References (81)

1. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington, VA: American Psychiatric Association Publishing.
2. Thornicroft G (2011) Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry 199, 441–442.
3. Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B et al. (2008) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders. CNS Drugs 22, 547–562.
4. Fraguas D, Correll CU, Merchán-Naranjo J et al. (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21, 621–645.
5. Weiden PJ, Mackell JA & McDonnell DD (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66, 51–57.
6. Ryu S, Nam HJ, Oh S et al. (2013) Eating-behavior changes associated with antipsychotic medications in patients with schizophrenia as measured by the drug-related eating behavior questionnaire. J Clin Psychopharmacol 33, 120–122.
7. Stip E, Lungu OV, Anselmo K et al. (2012) Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2, e128.
8. Theisen FM, Linden A, König IR et al. (2003) Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 110, 111–121.
9. Blouin M, Tremblay A, Jalbert ME et al. (2008) Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity 16, 1780–1787.
10. Thornley S, Russell B & Kydd R (2011) Carbohydrate reward and psychosis: an explanation for neuroleptic induced weight gain and path to improved mental health? Curr Neuropharmacol 9, 370–375.
11. Foussias G, Agid O, Fervaha G et al. (2014) Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol 24, 693–709.
12. Vancampfort D, Probst M, Knapen J et al. (2012) Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res 200, 73–78.
13. Carr VJ, Whiteford H, Groves A et al. (2012) Policy and service development implications of the second Australian National Survey of High Impact Psychosis (SHIP). Aust NZ J Psychiatry 46, 708–718.
14. Bornstein S, Schuppenies A, Wong M et al. (2006) Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Mol Psychiatry 11, 892–902.
15. Cuerda C, Velasco C, Merchán-Naranjo J et al. (2014) The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. Eur J Clin Nutr 68, 146–152.
16. Sharpe JK, Byrne NM, Stedman TJ et al. (2005) Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 105, 612–615.
17. Lett TAP, Wallace TJM, Chowdhury NI et al. (2012) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17, 242–266.
18. Reynolds GP & Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther 125, 169–179.
19. Werneke U, Taylor D & Sanders TA (2013) Behavioral interventions for antipsychotic induced appetite changes. Curr Psychiatry Rep 15, 1–10.
20. Sentissi O, Epelbaum J, Olié J-P et al. (2008) Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 34, 1189–1199.
21. Potvin S, Zhornitsky S & Stip E (2015) Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can J Psychiatry 60, S26–S34.
22. Yum SY, Caracci G & Hwang MY (2009) Schizophrenia and eating disorders. Psychiatr Clin North Am 32, 809–819.
23. Davison KM, Marshall-Fabien GL & Gondara L (2014) Sex differences and eating disorder risk among psychiatric conditions, compulsive behaviors and substance use in a screened Canadian national sample. Gen Hosp Psychiatry 36, 411–414.
24. Martin K, Woo J, Timmins V et al. (2016) Binge eating and emotional eating behaviors among adolescents and young adults with bipolar disorder. J Affect Disord 195, 88–95.
25. Katterman SN, Kleinman BM, Hood MM et al. (2014) Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: a systematic review. Eat Behav 15, 197–204.
26. Mangurian C, Sreshta N & Seligman H (2013) Food insecurity among adults with severe mental illness. Psychiatr Serv 64, 931–932.
27. Strike C, Rudzinski K, Patterson J et al. (2012) Frequent food insecurity among injection drug users: correlates and concerns. BMC Public Health 12, 1058.
28. Hoyumpa A (1980) Mechanisms of thiamin deficiency in chronic alcoholism. Am J Clin Nutr 33, 2750–2761.
29. De Hert M, Hudyana H, Dockx L et al. (2011) Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry. 26, 34–44.
30. Van Veggel M, Olofinjana O, Davies G et al. (2013) Clozapine and gastro-oesophageal reflux disease (GORD) – an investigation of temporal association. Acta Psychiatr Scand 127, 69–77.
31. Kishimoto T, De Hert M, Carlson HE et al. (2012) Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 25, 415–429.
32. Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68, 8–13.
33. Miller BJ, Paschall CB III & Svendsen DP (2008) Mortality and medical comorbidity among patients with serious mental illness. Mortality 6, 239–245.
34. Hennekens CH, Hennekens AR, Hollar D et al. (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150, 1115–1121.
35. Vancampfort D, Stubbs B, Mitchell A et al. (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14, 339–347.
36. Henderson DC, Vincenzi B, Andrea NV et al. (2015) Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2, 452–464.
37. Cohn TA & Sernyak MJ (2006) Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51, 492–501.
38. De Hert M, van Eyck D & De Nayer A (2006) Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21, S11–S15.
39. Van Winkel R, De Hert M, Van Eyck D et al. (2006) Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 67, 1493–1500.
40. Waterreus AJ & Laugharne J (2009) Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 190, 185–189.
41. De Hert M, Dekker J, Wood D et al. (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24, 412–424.
42. Curtis J, Newall HD & Samaras K (2012) The heart of the matter: cardiometabolic care in youth with psychosis. Earl Interv Psychiatry 6, 347–353.
43. Dipasquale S, Pariante CM, Dazzan P et al. (2013) The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatric Res 47, 197–207.
44. Gothelf D, Falk B, Singer P et al. (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159, 1055–1057.
45. DeMyer MK, Ward SD & Lintzenich J (1968) Comparison of macronutrients in the diets of psychotic and normal children. Arch Gen Psychiatry 18, 584–590.
46. Strassnig M, Brar JS & Ganguli R (2003) Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 29, 1745–1701.
47. McCreadie RG, Kelly C, Connolly M et al. (2005) Dietary improvement in people with schizophrenia Randomised controlled trial. Br J Psychiatry 187, 346–351.
48. Kant AK (2000) Consumption of energy-dense, nutrient-poor foods by adult Americans: nutritional and health implications. The third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 72, 929–936.
49. Public Health England (2014) National diet and nutrition survey results from years 1, 2, 3 and 4 (combined) of the rolling programme (2008/2009–2011/2012). https://www.gov.uk/ (accessed March 2016).
50. Larson CA & Carey KB (1998) Caffeine: brewing trouble in mental health settings? Prof Psychol Res Pr 29, 373–376.
51. Rihs M, Müller C & Baumann P (1996) Caffeine consumption in hospitalized psychiatric patients. Eur Arch Psychiatry Clin Neurosci 246, 83–92.
52. Taylor D, Paton C & Kapur S (2015) The Maudsley Prescribing Guidelines in Psychiatry. 12th edn. London: John Wiley & Sons.
53. Hägg S, Spigset O, Mjörndal T et al. (2000) Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 49, 59–63.
54. Raaska K, Raitasuo V, Laitila J et al. (2004) Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 94, 13–18.
55. Carrillo JA, Herraiz AG, Ramos SI et al. (1998) Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 18, 311–316.
56. Okusa MD & Crystal LJT (1994) Clinical manifestations and management of acute lithium intoxication. Am J Med 97, 383–389.
57. Leutgeb U (2000) Ambient iodine and lithium-associated clinical hypothyroidism. Br J Psychiatry 176, 495–496.
58. Dahan A & Altman H (2004) Food–drug interaction: grapefruit juice augments drug bioavailability – mechanism, extent and relevance. Eur J Clin Nutr 58, 1–9.
59. Flockhart DA (2012) An update on maois: dietary restrictions and drug interactions. J Clin Psychiatry 73, 31–31.
60. Davison KM, Ng E, Chandrasekera U et al. (2012) for Dietitians of Canada. Promoting Mental Health through Healthy Eating and Nutritional Care. Toronto: Dietitians of Canada. Access at: www.dietitians.ca/mentalhealth.
61. Curtis J, Watkins A, Rosenbaum S et al. (2015) Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Earl Interv Psychiatry 10, 267–276.
62. Teasdale S, Harris S, Rosenbaum S et al. (2014) Individual dietetic consultations in first episode psychosis: a novel intervention to reduce cardiometabolic risk. Community Ment Health J 51, 211–214.
63. Daumit GL, Dickerson FB, Wang NY et al. (2013) A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 368, 1594–1602.
64. Wu MK, Wang CK, Bai YM et al. (2007) Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 58, 544–550.
65. Bonfioli E, Berti L, Goss C et al. (2012) Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 12, 78.
66. Alvarez-Jimenez M, Hetrick SE, González-Blanch C et al. (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193, 101–107.
67. Bruins J, Jörg F, Bruggeman R et al. (2014) The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS ONE 9, e112276.
68. Teasdale S, Ward P, Rosenbaum S et al. (2017) Solving a weighty problem: a systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 210, 110–118.
69. Teasdale S, Ward P, Rosenbaum S et al. (2016) A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis. Br J Nutr 115, 1987–1993.
70. Kwan CL, Gelberg HA, Rosen JA et al. (2014) Nutritional counseling for adults with severe mental illness: key lessons learned. J Acad Nutr Diet 114, 369–374.
71. Menear M & Briand C (2014) Implementing a continuum of evidence-based psychosocial interventions for people with severe mental illness: part 1 – review of major initiatives and implementation strategies. Can J Psychiatry 59, 178–186.
72. Ozier AD & Henry BW (2011) Position of the american dietetic association: nutrition intervention in the treatment of eating disorders. J Am Diet Assoc 111, 1236–1241.
73. Rapoport L & Perry KN (2000) Do dietitians feel that they have had adequate training in behaviour change methods? J Hum Nutr Diet 13, 287–298.
74. Mitrou PN, Kipnis V, Thiébaut AC et al. (2007) Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 167, 2461–2468.
75. Estruch R, Ros E, Salas-Salvadó J et al. (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368, 1279–1290.
76. Stubbs B, Williams J, Gaughran F et al. (2016) How sedentary are people with psychosis? A systematic review and meta-analysis. Schizophr Res 171, 103–109.
77. Rosenbaum S, Tiedemann A, Sherrington C et al. (2014) Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry 75, 964–974.
78. Lederman O, Grainger K, Stanton R et al. (2016) Consensus statement on the role of Accredited Exercise Physiologists within the treatment of mental disorders: a guide for mental health professionals. Australas Psychiatry 24, 347–351.
79. Jacka FN, O'Neil A, Opie R et al. (2017) A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Medicine 15, 23.
80. Blanchard E & Samaras K (2014) Double jeopardy: diabetes and severe mental illness. The special needs of this vulnerable group (invited review). Diabetes Manag 4, 339–353.
81. Samaras K (2015) Diabetes and mental illness: challenges and practical progress. Endocrinol Today 4, 22–29.